Terms: = Liver cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
679 results:
1. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
2. Predicting effect of anti-PD-1/pd-l1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS.
Liu B; Shi J; Su R; Zheng R; Xing F; Zhang Y; Wang N; Chen H; Feng S
Front Immunol; 2024; 15():1370771. PubMed ID: 38707906
[TBL] [Abstract] [Full Text] [Related]
3. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma.
Li X; Pan YF; Chen YB; Wan QQ; Lin YK; Shang TY; Xu MY; Jiang TY; Pei MM; Tan YX; Dong LW; Wan XY
Cell Death Dis; 2024 Apr; 15(4):300. PubMed ID: 38684648
[TBL] [Abstract] [Full Text] [Related]
4. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
Du J; Zhang E; Huang Z
Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
[TBL] [Abstract] [Full Text] [Related]
5. The predictive value of pd-l1 expression in response to anti-PD-1/pd-l1 therapy for biliary tract cancer: a systematic review and meta-analysis.
Yoon SB; Woo SM; Chun JW; Kim DU; Kim J; Park JK; So H; Chung MJ; Cho IR; Heo J
Front Immunol; 2024; 15():1321813. PubMed ID: 38605964
[TBL] [Abstract] [Full Text] [Related]
6. Case report: Envafolimab causes local skin necrosis.
Liu JJ; Xu XY; Han H; Wang T; Zhang W; Cui J; Semenov M
Front Immunol; 2024; 15():1336311. PubMed ID: 38585260
[TBL] [Abstract] [Full Text] [Related]
7. Identification of molecular characteristics of hepatocellular carcinoma with microvascular invasion based on deep targeted sequencing.
Zheng L; Wang Y; Liu Z; Wang Z; Tao C; Wu A; Li H; Xiao T; Li Z; Rong W
Cancer Med; 2024 Apr; 13(7):e7043. PubMed ID: 38572921
[TBL] [Abstract] [Full Text] [Related]
8. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy.
Zeng Y; Huang J; Pang J; Pan S; Wu Y; Jie Y; Li X; Chong Y
Front Immunol; 2024; 15():1330644. PubMed ID: 38558804
[TBL] [Abstract] [Full Text] [Related]
9. Establishment of a murine hepatocellular carcinoma model by hydrodynamic injection and characterization of the immune tumor microenvironment.
Repáraz D; Casares N; Fuentes A; Navarro F
Methods Cell Biol; 2024; 185():79-97. PubMed ID: 38556453
[TBL] [Abstract] [Full Text] [Related]
10. Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Kim S; Ghiringhelli F; de la Fouchardière C; Evesque L; Smith D; Badet N; Samalin E; Lopez-Trabada Ataz D; Parzy A; Desramé J; Baba Hamed N; Buecher B; Tougeron D; Bouché O; Dahan L; Chibaudel B; El Hajbi F; Mineur L; Dubreuil O; Ben Abdelghani M; Pecout S; Bibeau F; Herfs M; Garcia ML; Meurisse A; Vernerey D; Taïeb J; Borg C
Lancet Oncol; 2024 Apr; 25(4):518-528. PubMed ID: 38547895
[TBL] [Abstract] [Full Text] [Related]
11. An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A; Morel D; Texier M; Sun R; Durand-Labrunie J; Rodriguez-Ruiz ME; Racadot S; Supiot S; Magné N; Cyrille S; Louvel G; Massard C; Verlingue L; Bouquet F; Bustillos A; Bouarroudj L; Quevrin C; Clémenson C; Mondini M; Meziani L; Tselikas L; Bahleda R; Hollebecque A; Deutsch E
Mol Cancer; 2024 Mar; 23(1):61. PubMed ID: 38519913
[TBL] [Abstract] [Full Text] [Related]
12. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
Ernst SM; Hofman MM; van der Horst TE; Paats MS; Heijboer FWJ; Aerts JGJV; Dumoulin DW; Cornelissen R; von der Thüsen JH; de Bruijn P; Hoop EO; Mathijssen RHJ; Koolen SLW; Dingemans AC
EBioMedicine; 2024 Apr; 102():105074. PubMed ID: 38507877
[TBL] [Abstract] [Full Text] [Related]
13. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
14. PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in pd-l1-negative metastatic lung adenocarcinoma: a real-world data.
Ge Y; Zhan Y; He J; Li J; Wang J; Wei X; Wang C; Gao A; Sun Y
J Cancer Res Clin Oncol; 2024 Mar; 150(3):135. PubMed ID: 38499838
[TBL] [Abstract] [Full Text] [Related]
15. FASN Inhibition Decreases MHC-I Degradation and Synergizes with pd-l1 Checkpoint Blockade in Hepatocellular Carcinoma.
Huang J; Tsang WY; Fang XN; Zhang Y; Luo J; Gong LQ; Zhang BF; Wong CN; Li ZH; Liu BL; Huang JL; Yang YM; Liu S; Ban LX; Chan YH; Guan XY
Cancer Res; 2024 Mar; 84(6):855-871. PubMed ID: 38486485
[TBL] [Abstract] [Full Text] [Related]
16. Real-World treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non-Small Cell Lung cancer: A Multiregional Chart Review in the United States, Europe, and Japan.
Leal TA; Dasgupta A; Latremouille-Viau D; Rossi C; Rai P; Barlesi F; Liu SV
JCO Glob Oncol; 2024 Mar; 10():e2300483. PubMed ID: 38484195
[TBL] [Abstract] [Full Text] [Related]
17. New advances in the study of PD-1/pd-l1 inhibitors-induced liver injury.
Yue M; Li C; Li G
Int Immunopharmacol; 2024 Apr; 131():111799. PubMed ID: 38460297
[TBL] [Abstract] [Full Text] [Related]
18. S100A9
Tu X; Chen L; Zheng Y; Mu C; Zhang Z; Wang F; Ren Y; Duan Y; Zhang H; Tong Z; Liu L; Sun X; Zhao P; Wang L; Feng X; Fang W; Liu X
J Exp Clin Cancer Res; 2024 Mar; 43(1):72. PubMed ID: 38454445
[TBL] [Abstract] [Full Text] [Related]
19. Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Zhang Q; Wei T; Jin W; Yan L; Shi L; Zhu S; Bai Y; Zeng Y; Yin Z; Yang J; Zhang W; Wu M; Zhang Y; Peng G; Roessler S; Liu L
J Hepatol; 2024 Feb; 80(2):293-308. PubMed ID: 38450598
[TBL] [Abstract] [Full Text] [Related]
20. Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers - how to push the gas after having released the brake.
Rakké YS; Buschow SI; IJzermans JNM; Sprengers D
Front Immunol; 2024; 15():1357333. PubMed ID: 38440738
[TBL] [Abstract] [Full Text] [Related]
[Next]